Ishita Drugs and Industries Limited is a manufacturer of various active pharma ingredients (APIs) (bulk actives and their salts), drug intermediates, excipients, and fine chemicals. The Company's APIs include sulpha drugs/sulfonamides, vitamins, fluoroquinolones, antibiotics, anthelmintics, iodides and citrates (salts), food additive/excipients, and others. Its drug intermediates include 4- Sulfonamido Phenyl Hydrazine Hydrochloride (Celecoxib Intermediate), 4- Chloro Phenyl Hydrazine Hydrochloride (intermediate for Indole Carboxylic Acid), L-Alanine Benzylester Tosylate, 5 Cyano Phthalide (Citalopram Intermediate), Indole 2 Carboxylic Acid, Ethyl 3-Benzoyl Acrylate, Hexa Methyl Disilazane, 5-Chloromethopabate, and others. Its fine chemicals include salicylanilide, para bromo toluene, pyridine hydrobromide, potassium phthalimide, nicotinic acid hydrazide, 3 amino pyridine, and methyl iodide. The Company has three manufacturing facilities located in the state of Gujarat.As of 25 May 2026, ISHITA DRUGS & INDUSTRIES LTD. share price is ₹82.00. The stock opened at ₹76.00, compared to its previous close of ₹77.11. During today's trading session, ISHITA DRUGS & INDUSTRIES LTD. share price moved in the range of ₹76.00 to ₹87.10, with an average price of ₹81.55 for the day. Looking at its last 52-week, the stock has touched a low of ₹76.00 and a high of ₹87.10.
The market capitalization of ISHITA DRUGS & INDUSTRIES LTD. is ₹23 Crs, with a P/E ratio of 26.0 and a dividend yield of 0.00%.